Carnosine [corrected] increases efficiency of DOPA therapy of Parkinson's disease: a pilot study.
The addition of the neuropeptide carnosine (beta-alanyl-L-histidine) as a food additive to the basic protocol of Parkinson's disease treatment results in significant improvement of neurological symptoms, along with increase in red blood cell Cu/Zn-SOD and decrease in blood plasma protein carbonyls and lipid hydroperoxides, with no noticeable change in platelets MAO B activity. The combination of carnosine with basic therapy may be a useful way to increase efficiency of PD treatment.
Boldyrev
Alexander
A
Research Center of Neurology, Russian Academy of Medical Sciences, Moscow, Russia. aaboldyrev@mail.ru
Fedorova
Tatiana
T
Stepanova
Maria
M
Dobrotvorskaya
Irina
I
Kozlova
Eugenia
E
Boldanova
Natalia
N
Bagyeva
Gulbakhar
G
Ivanova-Smolenskaya
Irina
I
Illarioshkin
Serguey
S
D000328:Adult; D000368:Aged; D002336:Carnosine / Q000008:administration & dosage*; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D010865:Pilot Projects; D050050:Protein Carbonylation / Q000187:drug effects; D013482:Superoxide Dismutase / Q000378:metabolism; D016896:Treatment Outcome
D004295:Dihydroxyphenylalanine; D002336:Carnosine; D013482:Superoxide Dismutase; D008995:Monoamine Oxidase